TIDMMTFB
Motif Bio PLC
08 September 2017
Motif Bio plc
("Motif Bio" or the "Company")
Motif Bio to Host Investor and Analyst Event on September 20,
2017 in New York
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage
biopharmaceutical company specialising in developing novel
antibiotics, today announces that the Company will host an Investor
and Analyst Event on Wednesday, September 20, 2017, in New York
from 8:00 am - 10:00 am ET, 1.00pm - 3.00pm UK time, 2.00pm-4.00pm
CET.
The event will focus on describing the unmet needs of
hospitalised patients with serious and life-threatening infections
and highlight the key attributes of iclaprim that, if approved, may
offer advantages over current standard of care antibiotics in three
well-defined groups of patients.
A faculty of infectious disease experts and Motif Bio senior
management will describe the clinical and economic challenges that
can lead to poor outcomes in high-risk, difficult-to-treat
hospitalised patients with serious infections. The potential role
that iclaprim can play in these patients will be described.
The agenda will include:
Introduction
Graham G. Lumsden, Chief Executive Officer, Motif Bio
Iclaprim Overview & REVIVE-1 (Ph. 3) Results
David Huang, PhD, MD, Chief Medical Officer, Motif Bio
William D. O'Riordan, MD, FACEP, Chief Medical Officer,
eStudySite, San Diego, CA
HABP Treatment Considerations & Unmet Needs
Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP Chair,
Infectious Disease Division, Summa Health, Akron, OH
Challenges in Managing Hospitalised ABSSSI Patients with Renal
Impairment
Francis Natale, PharmD, Director of Pharmacy, Methodist Hospital
Division, Thomas Jefferson University Hospitals, Philadelphia,
PA
Thomas Holland, MD, MSc-GH, Duke University School of Medicine
& Clinical Research Institute, Durham, NC
Economic Burden of High Risk Hospitalised ABSSSI Patients
Tom Lodise, PhD, PharmD, Albany College of Pharmacy & Health
Sciences, Albany, NY
Commercial Market Opportunity
Lynda Berne, M.S., M.B.A., Commercial Head, Motif Bio
If you are a member of the investment community and would like
to attend, please contact ir@motifbio.com.
The presentation will be webcast simultaneously and accessible
through the Investors - Events & Presentations section of the
Company's website at www.motifbio.com. A webcast replay, including
slides, will be available for 30 days following the event.
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive
Officer)
Robert Dickey IV (Chief Financial
Officer)
Walbrook PR Ltd. (UK +44 (0) 20 7933 8780 /
FINANCIAL PR & IR) motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980
541 893
Mike Wort Mob: +44 (0)7900
608 002
MC Services AG (EUROPEAN IR) +49 (0)89 210 2280
Raimund Gabriel raimund.gabriel@mc-services.eu
The Trout Group (US IR) +1 (646 )378-2938
Michael Gibralter mgibralter@troutgroup.com
Lazar Partners (US PR) motiflp@lazarpartners.com
Chantal Beaudry +1 (646) 871-8480
Amy Wheeler +1 (646) 871-8486
Note to Editors
About Motif Bio
Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage
biopharmaceutical company engaged in the research and development
of novel antibiotics designed to be effective against serious and
life-threatening infections in hospitalised patients caused by
multi-drug resistant bacteria, including MRSA. The Company's lead
product candidate, iclaprim, is being developed for high-risk MRSA
patient populations. The first proposed indication, and near-term
commercial opportunity, is for the treatment of acute bacterial
skin and skin structure infections (ABSSSI), one of the most common
bacterial infections, with 3.6 million patients hospitalised
annually in the U. S. The Company believes that iclaprim may be
suitable for first-line empiric therapy in ABSSSI patients,
especially those with renal impairment, with or without diabetes.
Unlike current standard of care antibiotics, in clinical trials to
date, nephrotoxicity has not been observed with iclaprim and dosage
adjustment has not been required in patients with renal
impairment.
Iclaprim has an underutilised mechanism of action compared to
other antibiotics. Clinical and microbiology data indicate iclaprim
has a targeted Gram-positive spectrum of activity, low propensity
for resistance development, fixed dose administration and
favourable tolerability profile. Additionally, data support that
the inactive metabolites of iclaprim clear through the kidneys. The
Company also plans to develop iclaprim for hospital acquired
bacterial pneumonia (HABP), including ventilator associated
bacterial pneumonia (VABP), as there is a high unmet need for new
therapies in this indication. A Phase 2 trial was conducted to
study iclaprim in patients with HABP. Iclaprim has been studied in
an animal model of chronic pulmonary MRSA infection which mimics
the pathophysiology observed in patients with cystic fibrosis.
Results from this study will be presented at IDWeek on October 6,
2017 in San Diego. Iclaprim has received Qualified Infectious
Disease Product (QIDP) designation from the FDA together with Fast
Track status. Upon acceptance by the FDA of a New Drug Application
(NDA), iclaprim will receive Priority Review status and, if
approved as a New Chemical Entity, will be eligible for 10 years of
market exclusivity in the U.S. from the date of first approval,
under the Generating Antibiotic Incentives Now Act (the GAIN Act).
In Europe, 10 years of data exclusivity is anticipated.
Forward-Looking Statements
This press release contains forward-looking statements. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that may cause Motif Bio's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Motif Bio believes that these factors
include, but are not limited to, (i) the timing, progress and the
results of clinical trials for Motif Bio's product candidates, (ii)
the timing, scope or likelihood of regulatory filings and approvals
for Motif Bio's product candidates, (iii) Motif Bio's ability to
successfully commercialise its product candidates, (iv) Motif Bio's
ability to effectively market any product candidates that receive
regulatory approval, (v) Motif Bio's commercialisation, marketing
and manufacturing capabilities and strategy, (vi) Motif Bio's
expectation regarding the safety and efficacy of its product
candidates, (vii) the potential clinical utility and benefits of
Motif Bio's product candidates, (viii) Motif Bio's ability to
advance its product candidates through various stages of
development, especially through pivotal safety and efficacy trials,
(ix) Motif Bio's estimates regarding the potential market
opportunity for its product candidates, and (x) the factors
discussed in the section entitled "Risk Factors" in Motif Bio plc's
Annual Report on Form 20-F filed with the SEC on May 1, 2017, which
is available on the SEC's web site, www.sec.gov. Motif Bio plc
undertakes no obligation to update or revise any forward-looking
statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALPMRTMBBMMPR
(END) Dow Jones Newswires
September 08, 2017 08:00 ET (12:00 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2024 to Jun 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Jun 2023 to Jun 2024